Factors associated with non-attendance at scheduled infant follow-up visits in an observational cohort of HIV-exposed infants in South Africa, 2012-2014.
AIDS Serodiagnosis
Adolescent
Adult
Antiretroviral Therapy, Highly Active
Child Health
Cross-Sectional Studies
Female
Follow-Up Studies
HIV
/ immunology
HIV Infections
/ diagnosis
Health Facilities
Humans
Infant
Infant, Newborn
Infectious Disease Transmission, Vertical
/ prevention & control
Lactation
Lost to Follow-Up
Middle Aged
Mothers
/ education
Postnatal Care
/ economics
Postpartum Period
Pregnancy
Risk Factors
South Africa
Surveys and Questionnaires
Travel
Young Adult
HIV-exposed infants
Missed visits
Postnatal care
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
16 Sep 2019
16 Sep 2019
Historique:
entrez:
19
9
2019
pubmed:
19
9
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Since 2001 the South African guidelines to improve child health and prevent vertical HIV transmission recommended frequent infant follow-up with HIV testing at 18 months postpartum. We sought to understand non-attendance at scheduled follow-up study visits up to 18 months, and for the 18-month infant HIV test amongst a nationally representative sample of HIV exposed uninfected (HEU) infants from a high HIV-prevalence African setting. Secondary analysis of data drawn from a nationally representative observational cohort study (conducted during October 2012 to September 2014) of HEU infants and their primary caregivers was undertaken. Participants were eligible (N = 2650) if they were 4-8 weeks old and HEU at enrolment. All enrolled infants were followed up every 3 months up to 18 months. Each follow-up visit was scheduled to coincide with each child's routine health visit, where possible. The denominator at each time point comprised HEU infants who were alive and HIV-free at the previous visit. We assessed baseline maternal and early HIV care characteristics associated with the frequency of 'Missed visits' (MV-frequency), using a negative binomial regression model adjusting for the follow-up time in the study, and associated with missed visits at 18 months (18-month MV) using a logistic regression model. The proportion of eligible infants with MV was lowest at 3 months (32.7%) and 18 months (31.0%) and highest at 12 months (37.6%). HIV-positive mothers not on triple antiretroviral therapy (ART) by 6-weeks postpartum had a significantly increased occurrence rate of 'MV-frequency' (adjusted incidence rate ratio, 1.2 (95% confidence interval (CI), 1.1-1.4), p < 0.0001). Compared to those mothers with ART, these mothers also increased the risk of '18-month-MV' (adjusted odds ratio, 1.3 (CI, 1.1-1.6), p = 0.006). Unknown infant nevirapine-intake status increased the rate of 'MV-frequency' (p = 0.02). Mothers > 24 years had a significantly reduced rate of 'MV-frequency' (p ≤ 0.01) and risk of '18-month-MV' (p < 0.01) compared to younger women. Shorter travel time to health facility lowered the occurrence of 'MV-frequency' (p ≤ 0.004). Late initiation of maternal ART and infant prophylaxis under the Option- A policy and extended travel time to clinics (measured at 6 weeks postpartum), contributed to higher postnatal MV rates. Mothers older than 24 years had lower MV rates. Targeted interventions may be needed during the current PMTCT Option B+ (lifelong ART to pregnant and lactating women at HIV diagnosis) to circumvent these risk factors and reduce missed visits during HIV-care.
Sections du résumé
BACKGROUND
BACKGROUND
Since 2001 the South African guidelines to improve child health and prevent vertical HIV transmission recommended frequent infant follow-up with HIV testing at 18 months postpartum. We sought to understand non-attendance at scheduled follow-up study visits up to 18 months, and for the 18-month infant HIV test amongst a nationally representative sample of HIV exposed uninfected (HEU) infants from a high HIV-prevalence African setting.
METHODS
METHODS
Secondary analysis of data drawn from a nationally representative observational cohort study (conducted during October 2012 to September 2014) of HEU infants and their primary caregivers was undertaken. Participants were eligible (N = 2650) if they were 4-8 weeks old and HEU at enrolment. All enrolled infants were followed up every 3 months up to 18 months. Each follow-up visit was scheduled to coincide with each child's routine health visit, where possible. The denominator at each time point comprised HEU infants who were alive and HIV-free at the previous visit. We assessed baseline maternal and early HIV care characteristics associated with the frequency of 'Missed visits' (MV-frequency), using a negative binomial regression model adjusting for the follow-up time in the study, and associated with missed visits at 18 months (18-month MV) using a logistic regression model.
RESULTS
RESULTS
The proportion of eligible infants with MV was lowest at 3 months (32.7%) and 18 months (31.0%) and highest at 12 months (37.6%). HIV-positive mothers not on triple antiretroviral therapy (ART) by 6-weeks postpartum had a significantly increased occurrence rate of 'MV-frequency' (adjusted incidence rate ratio, 1.2 (95% confidence interval (CI), 1.1-1.4), p < 0.0001). Compared to those mothers with ART, these mothers also increased the risk of '18-month-MV' (adjusted odds ratio, 1.3 (CI, 1.1-1.6), p = 0.006). Unknown infant nevirapine-intake status increased the rate of 'MV-frequency' (p = 0.02). Mothers > 24 years had a significantly reduced rate of 'MV-frequency' (p ≤ 0.01) and risk of '18-month-MV' (p < 0.01) compared to younger women. Shorter travel time to health facility lowered the occurrence of 'MV-frequency' (p ≤ 0.004).
CONCLUSION
CONCLUSIONS
Late initiation of maternal ART and infant prophylaxis under the Option- A policy and extended travel time to clinics (measured at 6 weeks postpartum), contributed to higher postnatal MV rates. Mothers older than 24 years had lower MV rates. Targeted interventions may be needed during the current PMTCT Option B+ (lifelong ART to pregnant and lactating women at HIV diagnosis) to circumvent these risk factors and reduce missed visits during HIV-care.
Identifiants
pubmed: 31526372
doi: 10.1186/s12879-019-4340-5
pii: 10.1186/s12879-019-4340-5
pmc: PMC6745773
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
788Références
AIDS. 2008 Aug 20;22(13):1679-81
pubmed: 18670232
Curr HIV/AIDS Rep. 2010 Nov;7(4):234-44
pubmed: 20820972
Int J Womens Health. 2011;3:359-66
pubmed: 22140322
BMC Int Health Hum Rights. 2012 Aug 10;12:13
pubmed: 22883969
J Int AIDS Soc. 2013 Jul 19;16:18588
pubmed: 23870277
ISRN AIDS. 2012 Jul 31;2012:589817
pubmed: 24052879
AIDS. 2013 Nov 13;27(17):2787-97
pubmed: 24056068
PLoS One. 2013 Sep 20;8(9):e74568
pubmed: 24073215
J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):e170-8
pubmed: 24759066
Trop Med Int Health. 2014 Nov;19(11):1360-6
pubmed: 25087778
J Epidemiol Community Health. 2015 Mar;69(3):240-8
pubmed: 25371480
J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):e26-32
pubmed: 25469521
J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):62-72
pubmed: 25501345
BMC Health Serv Res. 2014 Dec 19;14:646
pubmed: 25523349
BMC Public Health. 2015 Mar 07;15:228
pubmed: 25886161
S Afr Med J. 2014 Dec;104(12):874-80
pubmed: 26042271
Pediatr Res. 2016 Jun;79(6):838-45
pubmed: 26882367
J Int AIDS Soc. 2016 Mar 21;19(1):20662
pubmed: 27005750
J Glob Health. 2016 Dec;6(2):020405
pubmed: 27698999